La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Impel Pharmaceuticals Inc a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Impel Pharmaceuticals Inc..

Impel Pharmaceuticals Inc (OTC:IMPLQ) Azioni, Catena delle Opzioni

Impel Pharmaceuticals Inc

Truist Securities analyst Michael Ciarmoli maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Hold and raises the price target from $304 to $333.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Curtiss-Wright, Raises Price Target to $333

Benchmark analyst Todd Brooks reiterates Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) with a Hold.

Reiteration

LANC

Benchmark Reiterates Hold on Lancaster Colony

American statistician and writer Nate Silver on Friday described the 2024 U.S. presidential race is described as "a near coin flip," with Donald Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">narrowly leading Kamala Harris</a>.
What Happened: As of Oct. 31, Silver's <a href="https://www.natesilver.net/p/nate-silver-2024-president-election-polls-model">forecast</a> gives Trump a slight edge with a 53.4% chance of winning, compared to Harris's 46.2%.
This tight margin highlights the intense polarization and competitive nature of this election, which remains too close to call as polling data continues to evolve in critical swing states.
Silver's analysis of recent polls highlights shifting dynamics, particularly in Pennsylvania, where Trump now holds a 0.8-point lead in the polling average. 
The Pennsylvania shift could force Harris to rethink her path to victory if she cannot reclaim the state. Silver notes that losing Pennsylvania would require Harris to rely on a "two-state parlay," winning both Georgia or North Carolina alongside either Arizona or Nevada, which complicates her road to the White House. In SIlver&#8217;s <a href="https://x.com/NateSilver538/status/1852118017829671351">words</a>, the Vice President &#8220;may need backup plans&#8221; in case she does not win all three &#8220;Blue Wall&#8221; states.
Interestingly, Silver's model suggests Harris still maintains a slight edge in other essential battlegrounds, such as Wisconsin and Michigan. 
However, the high stakes in Pennsylvania illustrate just how crucial this state could be for either candidate. 
Silver also points out that AtlasIntel polls, which have historically shown more favorable results for Trump, gave him a strong performance in the most recent polling, while Echelon Insights reported a concerning five-point deficit for Harris in Pennsylvania.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41683531/michael-saylor-calls-microstrategy-the-public-equity-play-on-bitcoin-maximalism-heres-whos">Michael Saylor Calls MicroStrategy The &#8216;Public Equity Play On Bitcoin Maximalism&#8217;: Here&#8217;s Who&#8217;s Following This Approach</a>
What Prediction Markets Are Saying: Adding a unique perspective to the forecast are prediction markets like Kalshi and Polymarket.
Kalshi, a regulated prediction market, currently <a href="https://kalshi.com/">shows</a> Trump with a 57% chance of winning, while Harris trails at 43%.
This aligns closely with Silver's assessment but reflects a slightly stronger confidence in Trump's chances. 
Meanwhile, Polymarket <a href="https://polymarket.com/elections">provides</a> an even more pronounced view in Trump's favor, giving him a 62.6% probability of winning compared to Harris's 37.5%.
The gap between statistical models and prediction markets highlights differing interpretations of the data, with markets potentially factoring in variables beyond poll numbers.
To further illustrate these odds, Polymarket's state-by-state map gives insight into which regions lean towards each candidate. 
In this map, traditional Republican strongholds remain red, while Democratic-leaning states hold blue, with swing states painted in lighter shades, reflecting their uncertain outcomes. 
These insights show the regional split and reinforce Silver's commentary on the razor-thin margins in states that will likely decide the election outcome.
The close probabilities in both Silver's model and prediction markets like Kalshi and Polymarket signal an election with potential for last-minute shifts. 
Silver&#8217;s model remains dynamic, continuously adjusting based on new polling and data inputs, which means the probabilities for either candidate can change rapidly as the election nears.
What&#8217;s Next: In light of the uncertainty surrounding this election, upcoming events such as Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> on Nov. 19 will offer valuable insights into how financial markets might respond to the final outcome.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41680397/who-will-replace-gary-gensler-the-top-candidates-for-sec-chair-after-the-election">Who Will Replace Gary Gensler? The Top Candidates For SEC Chair After The Election</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Nate Silver Says Kamala Harris 'May Need Backup Plans' If The 'Blue Wal' Is Split But Sees The Race As 'A Near Coin Flip'

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy. It was the companies' first trial win in litigation over the products.
<a href="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial" title="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial">https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial</a>

RBGLY

Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks

Truist Securities analyst Youssef Squali maintains Cimpress (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPR#NASDAQ">CMPR</a>) with a Buy and lowers the price target from $120 to $110.

CMPR

Truist Securities Maintains Buy on Cimpress, Lowers Price Target to $110

Scotiabank analyst Mario Saric maintains ALLIED PROPS REAL ESTATE INV TST (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AP#TSX">AP</a>) with a Sector Outperform and lowers the price target from C$22 to C$21.75.

TSX:AP

Scotiabank Maintains Sector Outperform on ALLIED PROPS REAL ESTATE INV TST, Lowers Price Target to C$21.75

Truist Securities analyst William Stein maintains Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and raises the price target from $124 to $136.

Truist Securities Maintains Buy on Belden, Raises Price Target to $136

Truist Securities analyst Joel Fishbein maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Hold and raises the price target from $160 to $200.

TEAM

Truist Securities Maintains Hold on Atlassian, Raises Price Target to $200

Scotiabank analyst Nat Schindler maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Sector Outperform and raises the price target from $245 to $246.

AMZN

Scotiabank Maintains Sector Outperform on Amazon.com, Raises Price Target to $246

Truist Securities analyst William Stein maintains Arrow Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARW#NYSE">ARW</a>) with a Hold and lowers the price target from $141 to $120.

Truist Securities Maintains Hold on Arrow Electronics, Lowers Price Target to $120

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares are trading lower by 14% to $142.44 since Wednesday&#8217;s open after the company reported third-quarter results. The company posted revenue of $6.8 billion, which <a href="https://www.benzinga.com/news/earnings/24/10/41612007/amd-q3-earnings-revenue-beat-eps-in-line-data-center-up-122-significant-growth-opportunities-ahead-">exceeded analyst expectations</a> of $6.71 billion. Earnings per share aligned with projections at 92 cents.
What To Know: AMD&#8217;s data center segment was the driving force behind the company&#8217;s growth, achieving a 122% increase to $3.5 billion. The company also saw a 29% rise in client segment revenue, totaling $1.9 billion. 
However, gaming revenue experienced a steep decline of 69% to $462 million, and embedded revenue fell 25% to $927 million, though embedded revenue saw an 8% sequential quarterly increase.
CEO Lisa Su attributed AMD's results to high demand for the company's EPYC and Instinct data center products, as well as Ryzen processors in the PC segment. She also projected further growth opportunities across data center, client and embedded business sectors, driven by escalating demand for computing power. 
Looking ahead, AMD forecasts fourth-quarter revenue of $7.5 billion, representing a 22% year-over-year increase at the midpoint. Adjusted gross margins for the fourth-quarter are expected to remain consistent at 54%.
Read Also: <a href="https://www.benzinga.com/news/econ-s/24/11/41684710/us-economy-adds-only-12-000-jobs-in-october-sharply-misses-estimates-as-hurricane-strikes-pummel-hir">US Economy Adds Only 12,000 Jobs In October, Sharply Misses Estimates As Hurricanes, Strikes Pummel Hiring</a>
Analyst Reactions: The company's expansion in artificial intelligence (AI) and data center solutions has drawn positive reactions from analysts, who suggest AMD could increasingly challenge its main competitor, NVIDIA, in the AI domain. 
KeyBanc analyst John Vinh <a href="https://www.benzinga.com/analyst-ratings/price-target/24/10/41634850/amd-stock-drops-on-q4-outlook-as-10-analysts-highlight-long-term-ai-growth-opportuni">noted the importance</a> of AMD's MI300 chip, which is projected to generate $5 billion in revenue by 2024. 
Vinh believes that this chip could broaden customer adoption across cloud and AI applications, despite conservative fourth quarter guidance. 
Cantor Fitzgerald analyst C.J. Muse pointed out that AMD's AI progress with the MI300 may eventually generate $12 billion in revenue, supporting potential earnings growth by 2025 or 2026, even though he anticipates a short-term trading range for AMD shares.
Other analysts provided mixed assessments. Oppenheimer&#8217;s Rick Schafer commended AMD's rapid establishment of a competitive AI franchise, projected to surpass $5 billion in annual revenue, though he suggested that investor expectations might be overly ambitious. 
Meanwhile, Piper Sandler's Harsh Kumar highlighted strong GPU execution but acknowledged challenging guidance, noting that while AMD's GPU and server segments are promising, gaming and embedded segments pose risks.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/10/41634850/amd-stock-drops-on-q4-outlook-as-10-analysts-highlight-long-term-ai-growth-opportuni">AMD Stock Drops On Q4 Outlook As 10 Analysts Highlight &#8216;Long-Term AI Growth Opportunity,&#8217; Nvidia Rivalry</a>

AMD Stock Is Getting Hammered This Week: What's Going On?

MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) shares are trading higher on Friday after the company provided a solid fourth-quarter outlook and raised its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41665296/mastec-announces-third-quarter-2024-financial-results-and-increases-guidance-for-the-year" rel="noreferrer noopener">FY24 adjusted EPS&nbsp;guidance</a>.
On Thursday, the company reported&nbsp;revenue of $3.25 billion, missing the consensus of $3.42 billion.
The company&#8217;s 18-month backlog as of September&nbsp;30, stood at $13.9 billion, up&nbsp;$1.4 billion&nbsp;from the&nbsp;third quarter&nbsp;of 2023.
Adjusted EBITDA rose to $305.9 million from $271.1 million in the quarter, with margins expanding to 9.4% from 8.3% a year ago.
Adjusted EPS&nbsp;of $1.63&nbsp;topped <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of $1.23</a>.
Operating cash flow for the nine months came in at $649.9 million and net debt stood at $2.14 billion as of September 30.
Paul DiMarco, MasTec&#8217;s Executive Vice President and Chief Financial Officer, said, &#8220;We again significantly exceeded our cash flow targets, generating&nbsp;$278 million&nbsp;of cash flow from operations in the quarter and driving net debt leverage down to 2.2x. The macrotrends in our end markets remain favorable and we will prioritize capital allocation to take advantage of opportunities for growth.&#8221;
Outlook: MasTec sees fourth-quarter adjusted EPS of $1.29 versus the consensus of $0.94 and sales of $3.325 billion<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> against the estimate of $3.318 billion</a>.
MasTec raised FY24 adjusted EPS guidance from $3.03 to $3.75 compared to the $3.04 estimate and lowered sales guidance from $12.40 billion to $12.225 billion compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40115879/mastec-announces-second-quarter-2024-financial-results-and-updates-guidance-for-the-year" rel="noreferrer noopener">street view of $12.399 billion</a>.
Investors can gain exposure to the stock via Invesco S&amp;P Midcap 400 Pure Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFV#NYSE">RFV</a>) and SHRT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHRT#NYSE">SHRT</a>).
Price Action: MTZ shares are up 10.6% at $135.88 at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41683914" target="_blank" rel="noreferrer noopener">Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

Movers

Rydex ETF Trust S&P Midcap 400 Pure Value ETF

Tidal ETF Trust Gotham Short Strategies ETF

SHRT

Why Is Infrastructure Construction Company MasTec Stock Surging Today?

Trading Ideas

Connexa Sports Technologies Inc. - Common Stock

YYAI

Connexa Sports Shares Halted To The Downside; Stock Now Down -5.61%

Truist Securities analyst Youssef Squali maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $265 to $270.

Truist Securities Maintains Buy on Amazon.com, Raises Price Target to $270

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $305 to $310.

ALNY

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $310

Benchmark analyst Daniel Kurnos maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $200 to $215.

Benchmark Maintains Buy on Amazon.com, Raises Price Target to $215

Truist Securities analyst Michael Ciarmoli maintains Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) with a Buy and lowers the price target from $91 to $85.

Truist Securities Maintains Buy on Albany Intl, Lowers Price Target to $85

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $51 to $53.

AGIO

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53

Truist Securities analyst Mark Hughes maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Hold and raises the price target from $100 to $105.

Truist Securities Maintains Hold on Aflac, Raises Price Target to $105

Amazon.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares are moving higher on Friday after the company reported better-than-expected 2024 third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">earnings on Thursday.</a>
What Happened: Amazon reported EPS of $1.43, beating analyst estimates of $1.14. In addition, the company reported sales of $158.9 billion, representing a 11% year-over-year increase and beating analyst estimates of $157.20 billion.
The company saw year-over-year growth of 9% in North American sales, a 12% increase in International sales and a 19% rise in Amazon Web Services (AWS) sales.
For the 2024 fourth-quarter, the company anticipates sales between $181.5 billion and $188.5 billion and operating income between $16 billion and $20 billion.
Analyst Changes: Following the earnings report, multiple analysts issued <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">price target adjustments</a>.
AMZN Price Action: At the time of writing, Amazon shares are moving 6.68% higher at $198.85, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Related Link: <a href="https://www.benzinga.com/markets/equities/24/10/41674556/cathie-wood-bets-big-on-mark-zuckerberg-ark-pours-19m-into-meta-shares-dumps-palantir-and-tesla-">Cathie Wood Bets Big On Mark Zuckerberg: Ark Pours $19M Into Meta Shares, Dumps Palantir And Tesla Stock</a>
Image: Image via Shutterstock

What's Going On With Amazon Shares Friday?

Impel Pharmaceuticals (IMPLQ) has released an update. Impel Pharmaceuticals Inc. has completed a significant asset sale following its Chapter 11 ba...

Comments

Impel Pharmaceuticals Inc

Impel Pharmaceuticals Inc (IMPLQ) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO